CINECA IRIS Institutional Research Information System

FERRARO, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.701
AS - Asia 2.079
EU - Europa 1.593
SA - Sud America 340
AF - Africa 184
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 7
Totale 6.928
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.632
SG - Singapore 682
IT - Italia 464
CN - Cina 436
HK - Hong Kong 277
SE - Svezia 266
BR - Brasile 265
VN - Vietnam 208
GB - Regno Unito 168
DE - Germania 166
IN - India 151
FR - Francia 118
FI - Finlandia 88
JP - Giappone 82
CI - Costa d'Avorio 79
BG - Bulgaria 78
NL - Olanda 51
TR - Turchia 51
RU - Federazione Russa 41
SN - Senegal 37
CA - Canada 34
ID - Indonesia 28
PL - Polonia 28
AR - Argentina 24
AU - Australia 23
KR - Corea 23
NG - Nigeria 23
IQ - Iraq 20
AT - Austria 19
BD - Bangladesh 18
MX - Messico 18
ES - Italia 17
EC - Ecuador 15
SA - Arabia Saudita 14
PT - Portogallo 13
ZA - Sudafrica 12
IR - Iran 11
UZ - Uzbekistan 11
LT - Lituania 10
CZ - Repubblica Ceca 9
UA - Ucraina 9
VE - Venezuela 9
EG - Egitto 8
IE - Irlanda 8
MA - Marocco 8
PK - Pakistan 8
CO - Colombia 7
JO - Giordania 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
BE - Belgio 6
CL - Cile 6
PH - Filippine 6
RO - Romania 6
GR - Grecia 5
KZ - Kazakistan 5
PY - Paraguay 5
XK - ???statistics.table.value.countryCode.XK??? 5
AZ - Azerbaigian 4
CR - Costa Rica 4
DZ - Algeria 4
NP - Nepal 4
CH - Svizzera 3
DK - Danimarca 3
HR - Croazia 3
IL - Israele 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
LV - Lettonia 3
MY - Malesia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AL - Albania 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
GH - Ghana 2
GT - Guatemala 2
MK - Macedonia 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
IS - Islanda 1
JE - Jersey 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
Totale 6.920
Salva come PNG Salva come JPEG
Città #
Ashburn 433
Singapore 385
Hong Kong 272
San Jose 259
Santa Clara 243
Dallas 211
Chandler 148
Shanghai 144
Fairfield 91
Boardman 82
Florence 81
New York 80
Abidjan 79
Sofia 78
London 74
Los Angeles 73
Beijing 68
Munich 67
Ho Chi Minh City 66
Tokyo 62
Hanoi 52
Princeton 50
Helsinki 47
Pisa 42
Lauterbourg 39
Serra 39
Dakar 37
Houston 36
Wilmington 36
Istanbul 35
Lawrence 34
Milan 33
Turku 31
Woodbridge 30
Mumbai 29
Kent 27
Medford 27
Frankfurt am Main 25
Rome 25
Seattle 24
Lagos 23
Cambridge 21
Redwood City 21
Hyderabad 20
Rio de Janeiro 20
Council Bluffs 19
Massa 19
Hefei 18
Ann Arbor 17
Buffalo 17
Jakarta 17
Redondo Beach 17
Warsaw 17
São Paulo 16
Bremen 15
Da Nang 15
San Francisco 14
Chennai 13
Denver 13
San Diego 13
Amsterdam 12
Ogden 12
Chicago 11
Fuzhou 11
Washington 11
Dong Ket 10
Tashkent 10
Bengaluru 9
Düsseldorf 9
Johannesburg 9
Mexico City 9
Nuremberg 9
Atlanta 8
Belo Horizonte 8
Brooklyn 8
Curitiba 8
Livorno 8
Manchester 8
Marseille 8
Orem 8
Paris 8
Seoul 8
Amman 7
Baghdad 7
Haiphong 7
Naples 7
Ottawa 7
Phoenix 7
Roubaix 7
Vancouver 7
Vienna 7
Brasília 6
Brussels 6
Cascina 6
Jeddah 6
Jeju City 6
Lappeenranta 6
Montreal 6
Poplar 6
Quanzhou 6
Totale 4.358
Salva come PNG Salva come JPEG
Nome #
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 203
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 195
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 177
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 174
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 173
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 164
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 158
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 158
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 156
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis 155
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 149
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 148
The usefulness of listening social media for pharmacovigilance purposes: a systematic review 147
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 143
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 140
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 139
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 139
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 138
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies 137
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 134
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 133
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 132
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 132
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 131
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 130
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 128
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 126
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 126
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance 125
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 125
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 123
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 119
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 117
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 114
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 113
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 111
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 110
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 110
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 109
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 107
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 107
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 104
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 100
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 95
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 93
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 91
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 87
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 85
Communicating Drug Safety 83
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 78
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 77
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 76
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 73
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database 69
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data 69
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 64
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 58
null 56
Cases of acquired hemophilia A following COVID‐19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy 20
Totale 7.033
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.043
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.043
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021114 0 0 0 0 0 0 0 0 0 0 16 98
2021/2022621 12 16 70 75 89 88 25 32 31 19 44 120
2022/2023818 110 156 57 45 65 68 27 32 179 1 75 3
2023/2024682 17 34 42 16 65 99 85 48 38 37 104 97
2024/20252.210 38 87 102 176 149 263 188 78 224 261 247 397
2025/20262.390 236 186 280 251 292 143 409 112 215 251 15 0
Totale 7.033